Harrop: Drugmakers raise prices because we don’t haggle

If the government negotiated what Medicaid paid, market forces would keep prices in check.

By Froma Harrop

Syndicated columnist

Drugmakers rang in the new year by raising prices on hundreds of products; American prices, that is. Americans focused on the celebrations weren’t paying attention.

Allergan led the parade, hiking its prices by 10 percent on more than two dozen drugs. But note this: It didn’t raise the price of Botox, the anti-wrinkle treatment. Why? Because most users of Botox pay for it out of pocket. They can say, “I’m not bearing the extra freight. I think I’ll go another few months with crow’s-feet.”

Markets in which buyers and sellers haggle can bring reason to prices. Pharmaceuticals are special because when deemed essential to medical treatment, insurance covers them. The patient doesn’t get the full bill. Who pays? The people buying the insurance, whether private or government. That means employers pay, other buyers of private coverage pay and the taxpayers pay. There’s little in the way of a market check.

That’s why other governments have taken it upon themselves to negotiate the prices their people will pay for drugs. With a few exceptions, our government does not.

Thus, a prescription for the much-advertised Humira, which treats psoriatic arthritis, costs only an average of $822 in Switzerland but $2,669 here.

The 2003 Medicare drug benefit — that is, the creation of Medicare Part D — was a product of George W. Bush’s administration and a Republican Congress. It specifically forbade the government to negotiate drug prices for Medicare. The drug plans in Part D do temper prices somewhat, but Medicare, with its giant market, could do a lot better.

Donald Trump the candidate backed letting Medicare negotiate with drugmakers, an excellent idea. Trump the president promptly dropped it. And whom did he name as the secretary of health and human services but Alex Azar, a former top executive at Eli Lilly.

After the drugmakers’ New Year’s Eve price heist, both Trump and Azar expressed their displeasure in tweets. Does anyone remember them?

Last fall, Trump announced a project whereby Medicare Part B would use an “international pricing index” as a benchmark for setting prices for medications. Part B covers drugs administered by doctors and hospitals.

The idea could have promise. But it wasn’t announced until right before the midterm elections and hasn’t been talked about much since. Not a good sign.

Several states are taking the matter into their own hands. Vermont, for instance, is considering a program that would enable its residents to buy cheaper drugs from Canada. Olympia Snowe, a former Republican senator from Maine, made this a trademark proposal for addressing the high cost of drugs.

What these schemes have in common with Trump’s “international pricing index” is that they ask other countries to do the price bargaining for America. They pass the buck, our bucks.

The drug companies say that if Americans don’t cough up what they demand, they can’t afford the research to develop wonderful new products. In truth, drugmakers on average spend only 17 percent of their budgets on research and development. And nearly every new drug approved by the Food and Drug Administration started in research in government or university labs. The taxpayers made the investment, and Wall Street took the profits.

Even if we accept the industry’s argument, the question must be asked. If high prices are necessary for the development of wonderful new drugs, why are Americans the only people paying them? Doesn’t that make Americans truly the world’s suckers?

This is a Trumpian concept. Sadly, when it comes to addressing the exorbitant prices Americans pay for their drugs, Trump talks a far bigger game than he plays. We could be in for a surprise, but with a former Big Pharma executive running the HHS, don’t bet on it.

Follow Froma Harrop on Twitter @FromaHarrop. Email her at fharrop@gmail.com.

Talk to us

> Give us your news tips.

> Send us a letter to the editor.

> More Herald contact information.

More in Opinion

toon
Editorial cartoons for Sunday, July 13

A sketchy look at the news of the day.… Continue reading

Authorities search for victims among the rubble near Blue Oak RV park after catastrophic flooding on the Guadalupe River in Kerrville, Texas, on Sunday, July 6, 2025. The half-mile stretch occupied by two campgrounds appears to have been one of the deadliest spots along the Guadalupe River in Central Texas during last week’s flash floods. (Jordan Vonderhaar/The New York Times)
Editorial: Tragic Texas floods can prompt reforms for FEMA

The federal agency has an important support role to play, but Congress must reassess and improve it.

FILE — The sun sets over power lines in rural Ward County, Texas on Tuesday, May 20, 2025. Republicans plan to terminate billions of dollars in clean energy tax credits. Experts say that will mean more greenhouse gas emissions and more dangerous heat. (Paul Ratje/The New York Times)
Commentary: Bill will deliver dirtier energy at a higher price

Cuts to clean energy policy in the ‘Big Beautiful Bill’ will stifle our energy transition and cost us more.

Tufekci: ‘Garbage in, garbage out’ behind AI’s Nazi meltdown

That Elon Musk’s Grok chatbot defaulted to internet hate speech is concerning. Our acceptance is scarier.

Everett mayoral candidate had a role in budget problems

A mayoral candidate in Everett is being dishonest, blaming his opponent for… Continue reading

Social Security email was a false and partisan use of agency

I was appalled to get a spam email from the Social Security… Continue reading

Thanks for help with driver’s license renewal

I am writing to say that I was able to obtain my… Continue reading

2024 Presidential Election Day Symbolic Elements.
Editorial: Retain Escamilla, Binda on Lynnwood City Council

Escamilla was appointed a year ago. Binda is serving his first term.

A Volunteers of America Western Washington crisis counselor talks with somebody on the phone Thursday, July 28, 2022, in at the VOA Behavioral Health Crisis Call Center in Everett, Washington. (Ryan Berry / The Herald)
Editorial: Dire results will follow end of LGBTQ+ crisis line

The Trump administration will end funding for a 988 line that serves youths in the LGBTQ+ community.

toon
Editorial: Using discourse to get to common ground

A Building Bridges panel discussion heard from lawmakers and students on disagreeing agreeably.

Comment: Reforms to involuntary committment law can save lives

Washington state should consider changes New York made to protect those who can’t protect themselves.

Comment: Medicaid reforms will keep it for those most in need

Beyond the ‘sky is falling’ claims, the BBB’s reforms to Medicaid are fair and necessary to save it.

Support local journalism

If you value local news, make a gift now to support the trusted journalism you get in The Daily Herald. Donations processed in this system are not tax deductible.